Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Public ClinicalTrials.gov record NCT00101595. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of BMS-354825 in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate
Study identification
- NCT ID
- NCT00101595
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 96 participants
Conditions and interventions
Interventions
- Dasatinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2004
- Primary completion
- Nov 30, 2007
- Completion
- Nov 30, 2007
- Last update posted
- Apr 13, 2011
2005 – 2007
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution | Birmingham | Alabama | — | — |
| Local Institution | Anaheim | California | — | — |
| Local Institution | Los Angeles | California | — | — |
| Local Institution | Stanford | California | — | — |
| Local Institution | Vallejo | California | — | — |
| Local Institution | Jacksonville | Florida | — | — |
| Local Institution | Tampa | Florida | — | — |
| Local Institution | Atlanta | Georgia | — | — |
| Local Institution | Chicago | Illinois | — | — |
| Local Institution | Kansas City | Kansas | — | — |
| Local Institution | Boston | Massachusetts | — | — |
| Local Institution | St Louis | Missouri | — | — |
| Local Institution | Hackensack | New Jersey | — | — |
| Local Institution | New York | New York | — | — |
| Local Institution | Portland | Oregon | — | — |
| Local Institution | Pittsburgh | Pennsylvania | — | — |
| Local Institution | Nashville | Tennessee | — | — |
| Local Institution | Houston | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00101595, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 13, 2011 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00101595 live on ClinicalTrials.gov.